Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Scancell logo — Scancell is a clinical stage immunotherapy biotech company d...

Scancell

Scancell is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer.

Founded 1996 United Kingdom Oxford, United Kingdom 57 employees Post-IPO Equity Total: $15.65M Biotechnology, Health Care

General Information

Company Name Scancell
Founded Year 1996
Location United Kingdom Oxford, United Kingdom
Employees 57
Industries Biotechnology, Health Care
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Scancell. To contact Scancell, visit scancell.co.uk.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Scancell compare?

A PDF of Scancell and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Scancell soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Scancell

Scancell Ltd is a UK-based startup dedicated to using immunology to fight cancer. Established in 1996, the company focuses on developing innovative products that stimulate the immune system to treat or prevent cancer. Operating in the biotechnology and healthcare industries, Scancell aims to address the challenge of cancer's ability to evade the body's natural defense mechanisms. The company's cutting-edge technologies include the ImmunoBody® and Moditope® cancer vaccines, as well as the AvidiMab® and GlyMab® antibody platforms. Recently, Scancell secured a significant £10.70MPost-IPO Equity investment on 01 December 2023, marking a milestone in its growth trajectory. This investment was led by the Redmile Group, showcasing the market's confidence in the company's vision and potential. With its unwavering commitment to leveraging immunology against cancer, Scancell Ltd stands at the forefront of pioneering advancements in the fight against this formidable disease.

Business keywords: Immunology, Cancer, ImmunoBody, Moditope, Cancer Vaccines, AvidiMab, GlyMab, Antibody Platforms, Tumours, Immune System, Cancer Treatment, Prevention, Biopharmaceuticals

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity £10.70M 1
Redmile Group
Redmile Group
01 Dec 2023
Post IPO Equity £2.40M 1
Calculus Capital
Calculus Capital
04 Aug 2016
Venture Round £1.25M 3
Oxford Technology Management Oxford Capital HYGEA VCT PLC
Oxford Technology Management, Oxford Capital +1
25 May 2005
Venture Round £1.30M 4
Oxford Technology Management Oxford Capital HYGEA VCT PLC
Oxford Technology Management, Oxford Capital +2
27 Apr 2004
Venture Round Undisclosed 1
Oxford Technology Management
Oxford Technology Management
01 Aug 1999

Scancell Alternatives & Competitors

View All Alternatives
Scancell vs
Novelogics Biotechnology Inc.
Novelogics Biotechnology Inc. Canada

Pre-clinical stage biotech company developing an antibody immunotherapy drug for cancer using an “In...

Angel
1 employees
Biotechnology, Health Care
Scancell vs
Torigen, Inc.
Torigen, Inc.

Torigen Pharmaceuticals is focused on veterinary cancer care.

Series A
35 employees
Biotechnology, Health Care
Scancell vs
Mestag Therapeutics
Mestag Therapeutics United Kingdom

New therapies for inflammatory disease and cancer by targeting fibroblast immunology

Seed
40 employees
Biotechnology, Health Care
View all alternatives

FAQ About Scancell

Scancell is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer.
Scancell was founded in 1996.
Scancell is headquartered in Oxford, United Kingdom.
Scancell operates in Biotechnology and Health Care. Its work centres on Immunology, Cancer, ImmunoBody and Moditope.
Scancell has approximately 57 employees.
Scancell has completed 5 funding rounds, raising a total of $15.65M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Scancell include Novelogics Biotechnology Inc., Torigen, Inc., Mestag Therapeutics, Merus N.V., ImCheck Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Scancell and Novelogics Biotechnology Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Scancell, https://bouncewatch.com/company/scancell-ltd, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes